Molecular modelling suggested that polar groups appended to the arylsulfonyl residue in indoles 2, which are potential anticancer agents, could aid pharmaceutical properties without adversely affecting activity. A variety of substituted indoles were prepared using a one-pot Sonogashiratype method. A related indole, containing three Michael acceptor groups, has also been prepared.
Introduction
Investigations on heterocycles substituted with the 4-hydroxycyclohexa-2,5-dien-1-one ('quinol') fragment (a new pharmacophore in anticancer drug development) has led to the discovery of a number of potential therapeutic agents with novel biological properties. The prototypic benzothiazole-substituted quinol 1, where the quinol fragment acts as a double Michael acceptor, displayed selective antitumor activities against colon, renal, and breast cancer cell lines 2 with the small redox-regulatory protein thioredoxin (Trx) being the primary molecular target. 3 As expected, this agent also perturbs signalling events modulated by downstream Trx effectors (eg Hif-1 4 and VEGf 5 ) which have a major role in the tumor angiogenesis process triggered by cellular hypoxia. Subsequent investigations identified a more potent series of indolyl-quinols 2 which maintain the selectivity fingerprint against colon, renal and breast cancer cell lines in vitro. 6 Moreover, certain of the indole series show significant in vivo antitumor activity in mice bearing human mammary MDA-MB-435, colon HCT 116 and renal CAK-1 xenografts. 6 The original synthesis of indoles 2 was accomplished by lithiation of a substituted 1-arylsulfonylindole 3 with n-butyllithium in THF at -78 o C followed by addition to 4,4-dimethoxycyclohexa-2,5-dien-1-one with subsequent acid hydrolysis of the ketal protecting group. 6 We have recently described a more versatile route, employing a Sonogashira coupling with sequential cyclisation, from sulfonylated iodoanilines 4 and 4-ethynyl-4-hydroxycyclohexa-2,5-dienone 5 (Scheme 1). One of the limitations of the previously synthesised quinols was their limited water solubility. Preliminary molecular modelling suggested that polar groups appended to the arylsulfonyl residue in the indolyl-quinol series 2 would project outside the binding cavity of the Trx protein and be potentially available for profitable solvent interactions. One objective of the present work was to devise syntheses of variants of 2 with potentially improved pharmaceutical properties, based on the Sonogashira key step. In addition, molecular dynamics based docking studies were performed in order to analyse the non-covalent interactions of the indolyl-quinol (2: R = H, Ar = Ph) for its hypothesised Trx target. Observations of the resulting orientations adopted by the ligand in the human protein active site identified a non-active site cysteine specific to this protein which might be intercepted by an additional Michael acceptor fragment attached to the arylsulfonyl moiety. A route to such a compound has been achieved.
Results and Discussion
Our chosen strategy was to incorporate additional substitutents at the protected aniline stage prior to the Sonogashira step, starting from the previously described precursors 6a and 6b. The methyl esters 6a,b were efficiently hydrolysed (> 95%) in 10% aqueous KOH to the corresponding propanoic acids 6c,d and thence re-esterified to the t-butyl esters 6e,f with DMF Microwave-promoted Sonogashira cyclization of the sulfonamides 6 with alkyne 5 afforded the indolyl-quinols 7 in yields generally < 50% (Scheme 2), but no indoles 7c,d were obtained from the corresponding carboxylic acids 6c,d. (The preparation of the free acids 7c and 7d from 7a and 7b, respectively is described in the previous paper in the series.) 
Scheme 3
Starting from 2-nitroaniline 12 preparation of the sulphonamide 11 was not trivial. Anilines containing electron-withdrawing groups are known to yield significant amounts of disulfonylated products, 10 and this proved to be the case with 2-nitroaniline, so a two step process to 11, via the disulfonylated aniline 13 (87%) followed by TBAF mediated monodesulfonylation 10 (57%) was employed (Scheme 4). 
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The Heck reaction of 11 with methyl acrylate was performed using a variety of catalysts: the most successful was Nolan's palladium/imidazolium salt which yielded 10 in 52 % yield. 11 The nitro group was reduced to the corresponding amine 14 using iron(III) chloride 12 (69 %) and a Sandmeyer reaction furnished the iodide 9. Application of the Sonogashira reaction between 9 and 4-ethynyl-4-hydroxy-cyclohexa-2,5-dienone 5 yielded the desired indolyl-quinol 8 but in only 10 % yield. In conclusion, the synthesis of a number of novel substituted indoles, which are potential anticancer agents, has been described. Investigations into the biological properties of these compounds are continuing.
Experimental Section
General Procedures. Melting points were recorded on a Stuart Scientific SMP3 apparatus, and are uncorrected. IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR. Mass spectra were recorded on a Micromass LCT spectrometer using electrospray. NMR spectra were recorded on a Bruker Avance 400 instrument at 400. 
3-{4-[N-(2-Iodophenyl)sulfamoyl]phenyl}propanoic acid (6c).
Ester 6a (2.0 g; 4.5 mmol) was added to 10 % aqueous KOH (40 mL) and the mixture was refluxed for 0.5 h. 
N-(2-Iodophenyl)-4-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]benzene-sulfonamide (6h).
Similarly prepared from 6c and 1-methylpiperazine as described (above) as a white powder (1.46 g, 57%), mp 131. 5 
4-(3-Hydroxypropyl)-N-(2-iodophenyl)benzenesulfonamide (6i).
To a round-bottomed flask with attached distillation apparatus was added 6a (4.45 g, 10 mmol), borane-dimethyl sulfide complex (1 mL) and tetrahydrofuran (1 mL). The mixture was refluxed for 3 h, with dimethyl sulfide (bp 38 o C) being removed by distillation. Water (10 mL) was added, followed by K 2 CO 3
(1. 5 g 
N-(2-Iodophenyl)-4-(3-morpholinopropyl)benzenesulfonamide (6k).
To a stirred solution of 6j (1.04 g, 2.5 mmol) and morpholine (0.218 g, 2.5 mmol) in 1,2-dichloroethane (10 mL) under an atmosphere of nitrogen, was added sodium (triacetoxy)borohydride (0.75 g, 3.5 mmol). The mixture was stirred at room temperature for 4 h, then quenched with saturated aqueous NaHCO 3 (15 mL). The mixture was extracted with EtOAc, which was dried (MgSO 4 ) and concentrated, yielding 6k (1.15 g, 95%), mp 111. N-(2-Iodophenyl)-4-(3-(4-methylpiperazin-1-yl) propyl)benzenesulfon-amide (6l). Similarly prepared (above) from 6j and 1-methylpiperazine followed by crystallisation from aqueous ethanol (72%), mp 97-99. 
Preparation of Indolyl-quinols
To a 10 mL microwave vial containing a magnetic stirrer bar was added 4-ethynyl-4-hydroxycyclohexa-2,5-dienone 5 (0.39 g, 2.9 mmol), activated 2-iodoaniline 6 (2.5 mmol), DMAC (2.5 mL), diisopropylamine (0.5 mL) and water (0.1 mL). Nitrogen gas was gently bubbled through for 10 min, then tetrakis(triphenylphosphine)palladium (160 mg, 0.15 mmol) and copper iodide (48 mg, 0.25 mmol) were added. The vial was sealed, shaken, and heated at 100 o C (100 W) for 10 min under microwave conditions. The cooled mixture was diluted with DCM/water (200 mL: 1/1). The aqueous layer was extracted with DCM, and the combined organic layers dried and concentrated. 
